Currently, the main pharmacological treatments for AD (Knapskog et al., 2021; Briggs et al., 2016) are cholinesterase inhibitors (ChEIs), including donepezil, rivastigmine, and galantamine, which increase acetylcholine levels in the synaptic cleft and are used to treat mild to moderate AD. This evidence concerns the gene BCHE and Alzheimer disease.